News Desk — April 9, 2018 at 7:06 am — Updated: April 9, 2018 at 7:06 am

Novartis pays big premium to get hands on AveXis in $8.7 billion deal


ZURICH (Reuters) – Novartis plans to buy AveXis for $218 per share in a $8.7 billion (£6.17 billion) cash deal, adding a therapy hopeful for spinal muscular atrophy (SMA) to the Swiss drugmaker’s pipeline that is expected to reap billions in annual sales.

Leave A Comment Using Facebook (Website Comment Form Below)

Use the form below to post a comment via facebook

Leave a Reply

71 queries in 2.005 seconds.